Janssen Presents New Research at ECNP Calling for More Dialogue Between Psychiatrists and their Patients Living with Schizophrenia
The survey was conducted among 347 psychiatrists across eight European countries and found that psychiatrists limit or delay treatment option discussions with their patients living with schizophrenia. The research shows that opportunities exist for both psychiatrists and their patients living with schizophrenia to communicate more openly about treatment options, and importantly, the findings highlight the positive outlook psychiatrists have for the future of their patients living with schizophrenia.
Schizophrenia is a complex and chronic brain disorder, in which symptoms can be severe and disabling and can affect all aspects of a person’s daily life. Schizophrenia is typically a lifelong condition, but there are treatments that can be beneficial. Clinical guidelines recommend that the optimal treatment package is a combination of antipsychotic medication along with psychotherapy, psycho-education and self-help. Effective treatment may allow people with the condition to enjoy a more fulfilling, well rounded life, which may include returning to work or study, independent living and social relationships, which in turn can aid their recovery.1
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.
For more information on our activities in this area, we invite you to explore our neuroscience pages.
1. Lang U, Puls I, Muller DJ et al. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 2007;20(6):687-702.